D. Braumann

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015

C.-H. Köhne, Jacques De Grève, J. T. Hartmann et al. · Annals of Oncology · 2007 · 161 citations

Gastrointestinal Oncology, Medicine, Infusional 5-Fluorouracil/folinic Acid +8

Differentiation of Benign From Malignant Focal Splenic Lesions Using Sulfur Hexafluoride–Filled Microbubble Contrast-Enhanced Pulse-Inversion Sonography

Axel Stang, Handan Keles, Suna Hentschke et al. · American Journal of Roentgenology · 2009 · 62 citations

Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer

Meinolf Karthaus, Harald Balló, W. Abenhardt et al. · Oncology · 2005 · 48 citations

High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.

A R Zander, Nicolaus Kröger, M. Stockshläder et al. · PubMed · 1997 · 37 citations

Immunology, Pharmacotherapy, Immunotherapy +16

Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III study 40015

Jacques De Grève, C.H. Koehne, Julia Hartmann et al. · Journal of Clinical Oncology · 2006 · 35 citations

Cancer Management, Pharmacotherapy, Pre-clinical Pharmacology +18